摘要
Abstract
Objective Evaluating the efficacy and safety of pemetrexed alone versus docetaxel alone in second-line treatment of patients with advanced non-small cell lung cancer(NSCLC).Methods Followed by literature collection,assessment,data collection and extraction according Cochrane handbook for systematic reviews,and data analysis were performed by RevMan 5 .0 software.Re-sults 9 studies involving 1 439 cases were included.The results of Meta-analysis showed that for second-line treatment of advanced NSCLC,in efficacy part,there was no statistical difference between the two group in the effective rate(RR=1.26,95%CI:0.93-1.71,P=0.14),the disease control rate(RR=0.97,95%CI:0.88-1.06,P=0.49)and 1-year survival rate(RR=0.98,95%CI:0.74-1.29,P=0.87);in safety part,pemetrexed has a mild toxicity compare with docetaxel in Ⅲ-Ⅳ grade neutropenia(RR=0.17,95%CI:0.12-0.23,P<0.01),thrombocytopenia(RR=7.01,95%CI:1.87-26.29,P=0.004),the febrile neutropenia (RR=0.19,95%CI:0.07-0.52,P<0.01),alopecia[RR=0.09,95%CI:0.01-0.7,P=0.02]and diarrhea(RR=0.12,95%CI:0.02-0.65,P=0.01).There was no statistical difference in other adverse reactions(P>0.05).Conclusion Pemetrexed showed an equivalent efficacy to docetaxel in the second-line treatment of patients with advanced NSCLC,but it has better security.关键词
癌,非小细胞肺/Meta分析/培美曲塞/多西紫杉醇Key words
non-small-cell lung cancer/Meta-analysis/Pemetrexed/Docetaxel分类
医药卫生
